Washington, DC March 3, 2015
Abuse Deterrent Coalition Supports New Academic Research Highlighting the Need for Federal Policy Changes to Enhance Public Health and Safety
A new report in Therapeutic Advances in Drug Safety provides further evidence that, to improve public health and safety, we should focus on changing federal policies and prescription drug benefits by requiring abuse deterrent formulations in all Schedule II drugs. With mandatory abuse deterrent legislation poised to be introduced in Congress, shortly, Congress must lead by advising the FDA to implement this sensible public policy.
"We firmly believe that abuse deterrent technologies play an essential role, allowing access to critical medications for those with legitimate need, while curbing prescription drug abuse," asserts Dan Cohen, Forum Chair for the U.S. Abuse Deterrent Coalition. "It's reassuring that academic research leads to the same conclusion."